Bioengineered drug candidate can counter S. aureus infection

Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

Related Keywords

Aidan Omalley , Anna Okeeffe , Rita Chan , Ashley Dumont , Keenan Lacey , Victor Torres , Emily Henderson , Pathogen Program , Janssen Pharmaceutical Companies Of Johnson , Janssen Research Development , Langone Health Antimicrobial , Department Of Microbiology , Grossman School Of Medicine , Janssen Biotech Inc , Janssen Biotech , Cell Host , Lead Study Author , Health Antimicrobial Resistant Pathogen , Aidano Malley , Janssen Research , Janssen Pharmaceutical Companies , Antibiotic , Antibiotic Resistance , Ntibody , Bacteria , Fell , Medicine , Icrobiology , Olecule , Monoclonal Antibody , Athogen , Hagocytes , Protein , Research , Staphylococcus Aureus , Toxins ,